<PAGE>
- - --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHANGE ACT OF 1934
FILING NO. 2 FOR THE MONTH OF JANUARY, 2000
Visible Genetics Inc.
---------------------
(Exact name of Registrant)
700 Bay Street, Suite 1000, Toronto ON, Canada M5g 1Z6
------------------------------------------------------
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F
Form 20-F X Form 40-F
--- ---
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No X
--- ---
- - --------------------------------------------------------------------------------
<PAGE>
VISIBLE GENETICS INC.
On January 19, 2000, Visible Genetics Inc. (the "Company") issued press
release to announce that it has received notice of a patent suit. The press
release is filed as an exhibit to this Form 6-K.
The Company hereby incorporates by reference this Form 6-K into the
Company's outstanding Registration Statements on Form F-3 (File Nos. 333-67607,
333-68939, 333-91155 and 333-94649) and all of the Company's outstanding
Registration Statements on Form S-8 (including, but not limited to,
File Nos. 333-6454 and 333-8804).
Exhibit 1. Press Release issued January 19, 2000.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
VISIBLE GENETICS INC.
Date: January 19, 2000 By: /s/ Richard T. Daly
-------------------
Name: Richard T. Daly
Title: President and CEO
<PAGE>
Exhibit 1
[LETTERHEAD FOR VISIBLE GENETICS]
FOR IMMEDIATE RELEASE
CONTACTS:
Richard Daly (416) 813-3281 Bruno Maruzzo (416) 813-3271
CEO, Visible Genetics Inc. Investor Relations, Visible Genetics Inc
VISIBLE GENETICS INC. RECEIVES NOTICE OF PATENT SUIT
TORONTO, CANADA (JANUARY 19, 2000): VISIBLE GENETICS INC. (VGI, NASDAQ: VGIN)
announced today that the PE Biosystems Group has filed a lawsuit against VGI in
the United States District Court for the Northern District of California
claiming that VGI's DNA sequencing equipment infringes patents licensed to PE
Biosystems by the California Institute of Technology. PE Biosystems has not
served the complaint on the Company. The complaint offers no details to support
the allegation of infringement. VGI has previously studied these patents and has
received legal advice that it is not liable for any claims of infringement. VGI
believes that PE Biosystems' claim is without merit and plans to vigorously
defend the suit.
Visible Genetics Inc. is a leader in the emerging field of pharmacogenomics,
which uses genetic information in the identification and analysis of genes to
improve patient care and reduce healthcare costs. VGI manufactures and markets
high performance automated DNA sequencing systems and complete kits for the
analysis of genes linked to disease. The Company's OpenGene(TM) system employs
patented CLIP(TM) technology - a single-step, bi-directional sequencing method
that significantly reduces the time and cost involved in identifying clinically
relevant genetic information.
This press release contains forward-looking statements within the meaning of the
"safe harbor" provisions of the Private Securities Litigation Reform Act 1995.
These forward-looking statements are subject to risks and uncertainties and
other factors which may cause the Company's results to differ materially from
expectations. These include risks relating to possible outcomes of litigation
and other risks as detailed from time to time in the Company's SEC filings and
most recent Annual Report on Form 20-F. These forward-looking statements speak
only as of the date hereof. VGI disclaims any intent or obligation to update
these forward-looking statements.
###
